Eyenovia (NASDAQ:EYEN) Given “Neutral” Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Eyenovia (NASDAQ:EYEN) in a research report report published on Thursday,Benzinga reports. HC Wainwright currently has a $2.00 price target on the stock. HC Wainwright also issued estimates for Eyenovia’s FY2029 earnings at $1.40 EPS.

A number of other brokerages also recently weighed in on EYEN. William Blair reissued a “market perform” rating on shares of Eyenovia in a report on Friday, November 15th. Brookline Capital Management reaffirmed a “hold” rating on shares of Eyenovia in a research note on Friday, November 15th. Finally, LADENBURG THALM/SH SH restated a “neutral” rating on shares of Eyenovia in a report on Monday, November 18th.

Eyenovia Trading Down 14.3 %

Shares of Eyenovia stock opened at $2.04 on Thursday. Eyenovia has a 1-year low of $2.01 and a 1-year high of $205.60. The business’s fifty day moving average price is $6.67 and its two-hundred day moving average price is $33.30. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.58.

Eyenovia (NASDAQ:EYEN) last issued its earnings results on Tuesday, November 12th. The company reported ($8.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($10.40) by $1.60. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same period in the previous year, the business posted ($14.40) EPS. As a group, equities research analysts anticipate that Eyenovia will post -0.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Financial Management Network Inc. bought a new position in Eyenovia in the third quarter worth approximately $39,000. Nations Financial Group Inc. IA ADV increased its position in shares of Eyenovia by 78.6% during the third quarter. Nations Financial Group Inc. IA ADV now owns 90,900 shares of the company’s stock valued at $47,000 after acquiring an additional 40,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Eyenovia by 36.6% during the third quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock worth $288,000 after buying an additional 149,471 shares during the last quarter. 25.84% of the stock is owned by institutional investors and hedge funds.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.